Disopyramide

Disopyramide

Systematic (IUPAC) name
(RS)-4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide
Clinical data
Trade names	Norpace
AHFS/Drugs.com	monograph
MedlinePlus	a682408
Pregnancy cat.	B2(AU) C(US)
Legal status	POM (UK) ℞-only (US)
Routes	Oral, intravenous
Pharmacokinetic data
Bioavailability	High
Protein binding	50% to 65% (concentration-dependent)
Metabolism	Hepatic (CYP3A4-mediated)
Half-life	6.7 hours (range 4 to 10 hours)
Excretion	Renal (80%)
Identifiers
CAS number	3737-09-5 Y
ATC code	C01BA03
PubChem	CID 3114
DrugBank	APRD00507
ChemSpider	3002 Y
UNII	GFO928U8MQ Y
KEGG	D00303 Y
ChEBI	CHEBI:4657 Y
ChEMBL	CHEMBL517 Y
Chemical data
Formula	C21H29N3O
Mol. mass	339.475 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25) Y Key:UVTNFZQICZKOEM-UHFFFAOYSA-N Y
N(what is this?)  (verify)

Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication. It is a Class Ia antiarrhythmic (sodium channel blocker) used in the treatment of ventricular tachycardias. It has no effect on alpha or beta adrenergic receptors. It resembles quinidine but it has a marked anti-muscarinic effect on the heart, for this reason, it is not considered as a drug of 1st choice. It is also used in ventricular arrhythmia and supraventricular arrhythmia that might follow myocardial infarctions.

Cardiac adverse effects

• Acute heart failure[1]
• Severe hypotension

Extracardiac effects

• Dry mouth
• Constipation
• Urinary retention
• Blurred vision
• Glaucoma
• Rash
• Agranulocytosis

Additionally, disopyramide may enhance the hypoglycaemic effect of gliclazide, insulin, and metformin.

Chemistry

U.S. Patent 3,225,054

External links

• Disopyramide on RxList